Licensing | Partnership

Talem is an extension of the CRO and takes antibody discovery to the next level.  

 

Gain access to a vault of next-generation, 

fully-human antibodies to streamline your path to 

the clinic. 

 

Premium Programs

High-value targets

Talem preclinical experts match high value targets to fully vetted, premium antibody programs. Catapult your discovery project past the launch phase and accelerate to clinical success. Select from key targets for multiple indications, for licensing or co-development, including:  

 

• Discovery, preclinical and IND-enabling antibody programs  

 

• A broad range of indications: immuno-oncology, oncology, COVID-19, ophthalmology, inflammation, immunology, and infectious, rare/neglected, autoimmune, and heart diseases  

 

• Co-development of Talem internal, de novo and partner-specific programs 

Transgenic
Animals at Talem

We have optimized our powerful, custom, species-agnostic technologies for use with transgenic animal platforms to enable the discovery of highly diverse, fully human antibodies with superior clinical safety and efficacy as well as the lowest immunogenicity. The ability to select very specific, “needle-in-a-haystack” human antibodies via this advanced combination offers an entirely new avenue of therapeutic antibody discovery. Talem is the only CRO affiliate globally to offer these services as a partnership with OmniAb® transgenic (www.omniab.com) animals using their own license.

The PolyTope® Advantage

Talem has been actively involved in SARS-CoV-2 research since January 2020. One of its most advanced development programs, TATX-03 (anti-SARS-CoV-2 PolyTope® antibody cocktail), is a rationally designed, fully human, 4-antibody cocktail containing potently neutralizing antibodies against non-overlapping epitopes on SARS-CoV-2. Talem’s SARS-CoV-2 PolyTope® therapy is designed to reduce mutagenic escape risk with an emphasis on efficacy for every patient, variant, and strain of SARS-CoV-2, and has been developed with the goal of sustainable efficacy as the virus evolves, combining broadly characterized, neutralizing and synergistic antibodies that exhibit diverse epitope coverage.

> Polytope® TATX-03 Additional Information

Partner with Talem

Talem is focused on the discovery and development of next-generation, fully human, monoclonal, therapeutic antibodies targeted toward any disease indication.

With direct access to world-class, expedited and end-to-end technologies in antibody discovery, characterization, manufacturing and engineering, Talem accelerates novel, therapeutic antibody treatments to the clinic through strategic alliances and partnerships. 

Contact Us

For Business Development or Partnering Opportunities

The expertise at Talem is the culmination of 30 years of combined experience, thousands of programs, greater than 500 clients worldwide (including 70% of the top 20 pharmaceutical companies) and a unique HUB of intelligence to guide you to the clinic.  

 

For more information contact us:  

info@ipatherapeutics.com 

One Broadway, 14th floor
Cambridge, MA 02142, USA

For Investor Inquiries
Frédéric Chabot
investors@immunoprecise.com

ImmunoPrecise Antibodies
ipatherapeutics.com